Where does Sionna Therapeutics, Inc. Common Stock's cash flow data come from?

Every line is extracted from Sionna Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$85.57M-13.7%	-$75.27M-6.5%	-$70.68M+6.8%	-$75.84M-14.3%	-$66.32M-7.5%
Depreciation and amortization	$506K-1.0%	$511K-2.9%	$526K-16.0%	$626K-13.8%	$726K-1.0%
Stock-based compensation	$16.53M+37.0%	$12.07M+29.7%	$9.3M+32.5%	$7.02M+36.3%	$5.16M+39.0%
Net cash from operating activities	-$71.85M-8.4%	-$66.3M-7.9%	-$61.45M+3.8%	-$63.91M-14.3%	-$55.9M-5.9%
Capital expenditures	$291K-22.8%	$377K+88.5%	$200K+77.0%	$113K0.0%	$113K+319%
Net cash from investing activities	——	——	——	——	——
Net cash from financing activities	$5.53M-97.3%	$206.02M—	——	——	——
Net increase (decrease) in cash	——	——	——	——	——
Free cash flow	-$72.14M-8.2%	-$66.67M-8.1%	-$61.65M+3.7%	-$64.02M-14.3%	-$56.01M-6.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Sionna Therapeutics, Inc. Common Stock's cash flow data come from?: Every line is extracted from Sionna Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.